Prime Medicine, Common Etf Probability of Future Etf Price Finishing Under 15.2

PRME Etf  USD 2.69  0.05  1.89%   
Prime Medicine,'s future price is the expected price of Prime Medicine, instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Prime Medicine, Common performance during a given time horizon utilizing its historical volatility. Check out Prime Medicine, Backtesting, Portfolio Optimization, Prime Medicine, Correlation, Prime Medicine, Hype Analysis, Prime Medicine, Volatility, Prime Medicine, History as well as Prime Medicine, Performance.
  
Please specify Prime Medicine,'s target price for which you would like Prime Medicine, odds to be computed.

Prime Medicine, Target Price Odds to finish below 15.2

The tendency of Prime Etf price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay under $ 15.20  after 90 days
 2.69 90 days 15.20 
close to 99
Based on a normal probability distribution, the odds of Prime Medicine, to stay under $ 15.20  after 90 days from now is close to 99 (This Prime Medicine, Common probability density function shows the probability of Prime Etf to fall within a particular range of prices over 90 days) . Probability of Prime Medicine, Common price to stay between its current price of $ 2.69  and $ 15.20  at the end of the 90-day period is about 98.0 .
Given the investment horizon of 90 days the etf has the beta coefficient of 2.04 indicating as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Prime Medicine, will likely underperform. Additionally Prime Medicine, Common has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Prime Medicine, Price Density   
       Price  

Predictive Modules for Prime Medicine,

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Prime Medicine, Common. Regardless of method or technology, however, to accurately forecast the etf market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the etf market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.132.657.93
Details
Intrinsic
Valuation
LowRealHigh
0.255.0810.36
Details
13 Analysts
Consensus
LowTargetHigh
20.1722.1724.61
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.49-0.41-0.29
Details

Prime Medicine, Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Prime Medicine, is not an exception. The market had few large corrections towards the Prime Medicine,'s value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Prime Medicine, Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Prime Medicine, within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-0.54
β
Beta against Dow Jones2.04
σ
Overall volatility
0.44
Ir
Information ratio -0.1

Prime Medicine, Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Prime Medicine, for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Prime Medicine, Common can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Prime Medicine, generated a negative expected return over the last 90 days
Prime Medicine, has high historical volatility and very poor performance
Net Loss for the year was (198.13 M) with loss before overhead, payroll, taxes, and interest of (86.72 M).
Prime Medicine, Common currently holds about 146.66 M in cash with (165.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 62.0% of the company shares are owned by institutional investors
Latest headline from investing.com: Prime Medicines SWOT analysis gene editing firms stock faces pivotal 2025
The fund maintains 99.55% of its assets in stocks

Prime Medicine, Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Prime Etf often depends not only on the future outlook of the current and potential Prime Medicine,'s investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Prime Medicine,'s indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding91 M
Cash And Short Term Investments121.7 M

Prime Medicine, Technical Analysis

Prime Medicine,'s future price can be derived by breaking down and analyzing its technical indicators over time. Prime Etf technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Prime Medicine, Common. In general, you should focus on analyzing Prime Etf price patterns and their correlations with different microeconomic environments and drivers.

Prime Medicine, Predictive Forecast Models

Prime Medicine,'s time-series forecasting models is one of many Prime Medicine,'s etf analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Prime Medicine,'s historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the etf market movement and maximize returns from investment trading.

Things to note about Prime Medicine, Common

Checking the ongoing alerts about Prime Medicine, for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Prime Medicine, Common help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Prime Medicine, generated a negative expected return over the last 90 days
Prime Medicine, has high historical volatility and very poor performance
Net Loss for the year was (198.13 M) with loss before overhead, payroll, taxes, and interest of (86.72 M).
Prime Medicine, Common currently holds about 146.66 M in cash with (165.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.39, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Roughly 62.0% of the company shares are owned by institutional investors
Latest headline from investing.com: Prime Medicines SWOT analysis gene editing firms stock faces pivotal 2025
The fund maintains 99.55% of its assets in stocks

Other Information on Investing in Prime Etf

Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.